Background/Objectives: Indirect targeting of the subthalamic nucleus (STN) is commonly utilized at deep brain stimulation (DBS) centers around the world. The superiority of either midcommissural point (MCP)-based or red nucleus (RN)-based indirect targeting remains to be established. Methods: The location of the STN was determined and statistically compared to MCP- and RN-based predictions in 58 STN DBS patients, using a validated 3-tesla MRI protocol. The influence of additional neuroanatomical parameters on STN midpoint location was evaluated. Linear regression analysis was utilized to produce an optimized MCP/RN targeting model. Targeting coordinates at 1.5 T were compared to results at 3 T. Results: Accuracy and precision for RN-based targeting was superior to MCP-based targeting to predict STN midpoint location for each coordinate dimension (p < 0.01 and p < 0.05, respectively). RN-based targeting was statistically equivalent to an optimized regression-based targeting strategy incorporating multiple neuroanatomical parameters, including third-ventricle width and overall brain size. RN-based targeting at 1.5 T yielded equivalent coordinates to targeting at 3 T. Conclusions: RN-based targeting is statistically superior to MCP-based STN targeting and accommodates broad variations in neuroanatomical parameters. Neurosurgeons utilizing indirect targeting of the STN may consider favoring RN-based over MCP-based indirect targeting methods.

Keywords:
Deep brain stimulation, Magnetic resonance imaging, Subthalamic nucleus, Red nucleus, Parkinson’s disease, Targeting
1.
Patil PG, Conrad EC, Aldridge JW, Chenevert TL, Chou KL: The anatomical and electrophysiological subthalamic nucleus visualized by 3-T magnetic resonance imaging. Neurosurgery 2012;71:1089-1095.
2.
Deuschl G, Schade-Brittinger C, Krack P, et al: A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908.
3.
Schuepbach WM, Rau J, Knudsen K, et al: Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013;368:610-622.
4.
Benabid AL, Chabardes S, Mitrofanis J, Pollak P: Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 2009;8:67-81.
5.
Hamel W, Fietzek U, Morsnowski A, Schrader B, Herzog J, Weinert D, Pfister G, Müller D, Volkmann J, Deuschl G, Mehdorn HM: Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: evaluation of active electrode contacts. J Neurol Neurosurg Psychiatry 2003;74:1036-1046.
6.
Lanotte MM, Rizzone M, Bergamasco B, Faccani G, Melcarne A, Lopiano L: Deep brain stimulation of the subthalamic nucleus: anatomical, neurophysiological, and outcome correlations with the effects of stimulation. J Neurol Neurosurg Psychiatry 2002;72:53-58.
7.
Saint-Cyr JA, Hoque T, Pereira LCM, Dostrovsky JO, Hutchison WD, Mikulis DJ, Abosch A, Sime E, Lang AE, Lozano AM: Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. J Neurosurg 2002;97:1152-1166.
8.
Yelnik J, Damier P, Demeret S, Gervais D, Bardinet E, Bejjani BP, François C, Houeto JL, Arnule I, Dormont D, Galanaud D, Pidoux B, Cornu P, Agid Y: Localization of stimulating electrodes in patients with Parkinson disease by using a three-dimensional atlas-magnetic resonance imaging coregistration method. J Neurosurg 2003;99:89-99.
9.
Daniluk S, Davies KG, Ellias SA, Novak P, Nazzaro JM: Assessment of the variability in the anatomical position and size of the subthalamic nucleus among patients with advanced Parkinson's disease using magnetic resonance imaging. Acta Neurochir 2009;152:201-210.
10.
Benabid AL: Deep brain stimulation for Parkinson's disease. Curr Opin Neurobiol 2003;13:696-706.
11.
Temel Y, Blokland A, Steinbusch HW, Visser-Vandewalle V: The functional role of the subthalamic nucleus in cognitive and limbic circuits. Prog Neurobiol 2005;76:393-413.
12.
Temel Y, Kessels A, Tan S, Topdag A, Boon P, Visser-Vandewalle V: Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review. Parkinsonism Relat Disord 2006;12:265-272.
13.
Voon V, Kubu C, Krack P, Houeto JL, Tröster AI: Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord 2006;21:S305-S327.
14.
Brunenberg EJ, Platel B, Hofman PA, Ter Haar Romeny BM, Visser-Vandewalle V: Magnetic resonance imaging techniques for visualization of the subthalamic nucleus. J Neurosurg 2011;115:971-984.
15.
Bejjani BP, Dormont D, Pidoux B, Yelnik J, Damier P, Arnulf I, Bonnet AM, Marsault C, Agid Y, Philippon J: Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance. J Neurosurg 2000;92:615-625.
16.
Hamani C, Richter EO, Andrade-Souza Y, Hutchison W, Saint-Cyr JA, Lozano AM: Correspondence of microelectrode mapping with magnetic resonance imaging for subthalamic nucleus procedures. Surg Neurol 2005;63:249-253.
17.
Andrade-Souza YM, Schwalb JM, Hamani C, Eltahawy H, Hoque T, Saint-Cyr J, Lozano AM: Comparison of three methods of targeting the subthalamic nucleus for chronic stimulation in Parkinson's disease. Neurosurgery 2005;56:360-368.
18.
Benabid AL, Krack P, Benazzouz A, Limousin P, Koudsie A, Pollak P: Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: methodologic aspects and clinical criteria. Neurology 2000;55:S40-S44.
19.
Starr PA, Christine CW, Theodosopoulos PV, Lindsey N, Byrd D, Mosley A, Marks WJ Jr: Implantation of deep brain stimulators into the subthalamic nucleus: technical approach and magnetic resonance imaging-verified lead locations. J Neurosurgery 2002;97:370-387.
20.
Ashkan K, Blomstedt P, Zrinzo L, Tisch S, Yousry T, Limousin-Dowsey P, Hariz M: Variability of the subthalamic nucleus: the case for direct MRI guided targeting. Br J Neurosurg 2007;21:197-200.
21.
Caire F, Maubon A, Moreau JJ, Cuny E: The mamillothalamic tract is a good landmark for the anterior border of the subthalamic nucleus on axial MR images. Stereotact Funct Neurosurg 2011;89:286-290.
22.
Deogaonkar M, Freitas T, Machado A, Rezai A: Subthalamic nucleus targeting using interpeduncular cistern as an internal landmark. Neurosurgery 2011;69:225-229.
23.
Hariz MI, Fodstad H: Do microelectrode techniques increase accuracy or decrease risks in pallidotomy and deep brain stimulation? Stereotact Funct Neurosurg 1999;72:157-169.
24.
Mai JK, Assheuer J, Paxinos G: Atlas of the Human Brain, ed 2. Amsterdam, Boston, Elsevier Academic Press, 2004.
25.
Zonenshayn M, Rezai AR, Mogilner AY, Beric A, Sterio D, Kelly PJ: Comparison of anatomic and neurophysiological methods for subthalamic nucleus targeting. Neurosurgery 2000;47:282-294.
26.
Cuny E, Guehl D, Burbaud P, Gross C, Dousset V, Rougier A: Lack of agreement between direct magnetic resonance imaging and statistical determination of a subthalamic target: the role of electrophysiological guidance. J Neurosurg 2002;97:591-597.
27.
Cheng CH, Huang HM, Lin HL, Chiou SM: 1.5 T versus 3 T MRI for targeting subthalamic nucleus for deep brain stimulation. Br J Neurosurg 2014;28:467-470.
28.
Slavin K, Thulborn K, Wess C, Nersesyan H: Direct visualization of the human subthalamic nucleus with 3 T MR imaging. Am J Neuroradiol 2006;27:80-84.
29.
Danish SF, Jaggi JL, Moyer JT, Finkel L, Baltuch GH: Conventional MRI is inadequate to delineate the relationship between the red nucleus and subthalamic nucleus in Parkinson's disease. Stereotact Funct Neurosurg 2006;84:12-18.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.